about us

About us

Headquartered in Suzhou Industrial Park, Suzhou Royaltech Med Co., Ltd. was founded in July 2016.  In July 2017, a wholly-owned subsidiary, Shanghai Royaltechmed Co., Ltd. was set up in Shanghai International Medical Zone.  As a high-standard innovation center of biological drugs, Shanghai Royaltech focuses on CMC development of innovative tumor vaccine, and fast clinical application of up-to-date cell immunotherapy.

Since establishment, we have submitted several patents for invention to the State Intellectual Property Office.  We focus on development of innovative tumor vaccine, and fast clinical application of up-to-date cell immunotherapy. Our R&D pipeline covers mRNA, oncolytic virus, bacteria, AAV, cell therapy platform and so on.  Our core management team is from top 10 big pharma, with an average of 15 years of R&D and management experience. Our scientists have excellent capability on molecular biological engineering, target discovery and verification, pre-clinical R&D, quality control and assurance, and clinical trials of cell immunotherapy. On the strength of our rich experience on target biomarker, target discovery and verification, and global multicenter clinical trials, we are advancing an internationally competitive R&D pipeline.